Bliss GVS Pharma LimitedQ1 FY27 Results & Financial Update
Bliss GVS Pharma Limited: Q1 FY27 consolidated results and company financials – revenue ₹285.58 Cr, PAT ₹51.37 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Bliss GVS Pharma price & chart
Market price₹652.00
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Bliss GVS Pharma Q1 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
For the quarter ended June 30, 2026 (Q1 FY27), Bliss GVS reported consolidated total income from operations of INR 285.58 crore, reflecting an expansion compared to INR 242.92 crore in the corresponding period of the previous year.
Total consolidated income, which includes other income streams, stood at INR 295.18 crore for the first quarter of fiscal 2027.
Profit before tax (PBT) for the quarter rose to INR 75.48 crore compared to INR 63.11 crore reported in Q1 FY26, demonstrating improved operational performance.
Consolidated net profit after tax (PAT) reached INR 51.37 crore for Q1 FY27, compared with INR 44.36 crore in the same period last year.
Basic earnings per share (EPS) for the quarter was INR 4.73 (diluted EPS of INR 4.65), up from basic EPS of INR 4.08 (diluted EPS of INR 4.04) in Q1 FY26.
Sequential comparison shows total revenue from operations advancing from INR 268.15 crore in Q4 FY26 to INR 285.58 crore in Q1 FY27, with net profit moving upward from INR 37.00 crore in the preceding quarter.
Bliss GVS Pharma Limited posted consolidated total income from operations of INR 285.58 crore for the quarter ended June 30, 2026, marking top-line growth compared to INR 242.92 crore in the corresponding quarter of the previous year and INR 268.15 crore in the preceding quarter.
Total consolidated income, inclusive of other operating items, reached INR 295.18 crore for Q1 FY27, compared with INR 249.29 crore a year earlier and INR 275.05 crore in Q4 FY26.
01 · Business model
What does Bliss GVS Pharma do?
Bliss GVS Pharma Limited is a pharmaceutical company engaged in the development, manufacturing, and marketing of a diverse portfolio of pharmaceutical formulations and products.
The company maintains its registered office in Andheri (East), Mumbai, and operates manufacturing facilities including units located at Palghar in Maharashtra.
Bliss GVS distributes its specialized therapeutic products across domestic and international markets, focusing on healthcare segments such as anti-malarial, analgesic, and other essential formulations.
02 · Financial snapshot
Current-quarter financial snapshot
| Metric | Q1 FY27 |
|---|---|
| Revenue from operations | ₹285.58 Cr |
| Total income | ₹295.18 Cr |
| Profit before tax | ₹75.48 Cr |
| Profit after tax | ₹51.37 Cr |
| EPS | ₹4.65 |
Financial interpretation
What the reported numbers mean
Profit after tax represented 18.0% of reported quarterly operating revenue. This is a calculated net-profit-to-sales ratio, not a company-reported operating margin. It measures the outcome after expenses and tax; it does not, by itself, establish how margins changed versus another period.
Profit before tax was equivalent to 26.4% of quarterly operating revenue. The distinction between pre-tax and post-tax profit matters when interpreting earnings; neither ratio identifies an underlying cost driver without a properly matched comparative period.
Total income exceeded operating revenue by ₹9.60 crore. This is the disclosed difference between the two lines, not incremental sales. The distinction matters when assessing how much of the quarter’s reported income came from the operating top line.
Ratios above are calculated from the reported quarterly figures. They are analytical descriptions, not company-reported margin guidance or an investment recommendation.
03 · Why it moved
Why the quarter looked the way it did
What drove revenue
Consolidated revenue from operations reached INR 285.58 crore in Q1 FY27, marking growth over both the INR 242.92 crore recorded in Q1 FY26 and the INR 268.15 crore posted in Q4 FY26.
Total income reached INR 295.18 crore for the quarter, supported by core pharmaceutical sales and secondary operating receipts.
Revenue from operations reached INR 285.58 crore in Q1 FY27, supported by steady demand across core pharmaceutical product categories.
Total income reached INR 295.18 crore, bolstered by non-operating income components included in the consolidated results.
What drove margins
Profit before tax expanded to INR 75.48 crore in Q1 FY27 from INR 63.11 crore in Q1 FY26, while net profit rose to INR 51.37 crore, indicating healthy bottom-line conversion.
Profit before tax grew to INR 75.48 crore, yielding a higher PBT margin relative to revenue compared to preceding periods, aided by operational efficiencies.
04 · Reported developments
What changed operationally
Consolidated net profit for Q1 FY27 increased to INR 51.37 crore from INR 44.36 crore in Q1 FY26.
Quarterly operating revenue improved sequentially from INR 268.15 crore in Q4 FY26 to INR 285.58 crore in Q1 FY27.
Net profit increased from INR 37.00 crore in Q4 FY26 to INR 51.37 crore in Q1 FY27, accompanied by higher basic EPS of INR 4.65.
05 · Beyond the numbers
What changed beyond the numbers
Reported update
Board Approval and Filing
The unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, were approved by the Board of Directors on August 12, 2026.
06 · Previous-quarter changes
What changed since the previous quarter
Revenue from operations grew from INR 268.15 crore in Q4 FY26 to INR 285.58 crore in Q1 FY27.
Net profit increased from INR 37.00 crore in Q4 FY26 to INR 51.37 crore in Q1 FY27.
07 · Key Q&A
The quarter, answered directly
What does Bliss GVS Pharma do?
Bliss GVS Pharma Limited is a pharmaceutical company engaged in the development, manufacturing, and marketing of a diverse portfolio of pharmaceutical formulations and products.
What is the clearest takeaway from Q1 FY27?
For the quarter ended June 30, 2026 (Q1 FY27), Bliss GVS reported consolidated total income from operations of INR 285.58 crore, reflecting an expansion compared to INR 242.92 crore in the corresponding period of the previous year.
What drove revenue or demand?
Consolidated revenue from operations reached INR 285.58 crore in Q1 FY27, marking growth over both the INR 242.92 crore recorded in Q1 FY26 and the INR 268.15 crore posted in Q4 FY26.
What mattered most for margins or profitability?
Profit before tax expanded to INR 75.48 crore in Q1 FY27 from INR 63.11 crore in Q1 FY26, while net profit rose to INR 51.37 crore, indicating healthy bottom-line conversion.
What changed operationally beyond the headline numbers?
The unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, were approved by the Board of Directors on August 12, 2026.
What should the next disclosure help confirm?
Monitor upcoming quarterly disclosures for the continuation of revenue expansion and margin trends.
08 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
09 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Subsequent Quarter Performance: Monitor upcoming quarterly disclosures for the continuation of revenue expansion and margin trends.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.